<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376025</url>
  </required_header>
  <id_info>
    <org_study_id>KB001</org_study_id>
    <nct_id>NCT00376025</nct_id>
  </id_info>
  <brief_title>Antioxidant Supplementation in Patients With Kashin-Beck Disease</brief_title>
  <official_title>Study of the Effects of Antioxidant Supplementation in Patients Suffering From Kashin-Beck Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Humanitarian Solutions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Houston - Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Innovative Humanitarian Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether antioxidant supplementation can have a
      positive health effect on patients suffering from Kashin-Beck disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current research regarding Kashin-Beck disease, (KBD) have identified dramatic deficiencies
      of both selenium and iodine in patients with this disease. Initial supplementation of these
      trace minerals provided no measurable benefit to the affected population. Research conducted
      by Innovative Humanitarian Solutions, suggests that such deficiencies may not be causal, but
      markers of an underlying condition of extreme oxidative stress brought on by the improper
      functioning of the Glutathione Peroxidase enzyme in synthesizing H202 during periods of
      critical cellular development, primarily in mesenchymal cell development.

      The purpose of this trial is to determine the efficacy of antioxidant supplementation in
      aiding the Glutathione Peroxidase enzyme in its proper function and thereby reducing
      oxidative stress and enabling the uptake of selenium and iodine which are necessary for
      proper bone growth and development.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on FLACC or Word Graphic pain rating scale at 3, 6, 9 months</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in serum selenium concentrations at 6 months</measure>
    <time_frame>Six Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Kashin-Beck Disease</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Biological Antioxidant Supplementation</intervention_name>
    <description>Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed patients with Kashin-Beck disease

        Exclusion Criteria:

          -  less than 24 hours from admission to ICU

          -  Patients who are moribund

          -  Lack of commitment to program

          -  Absolute contraindication to enteral nutrients

          -  Severe acquired brain injury

          -  Pregnant or lactating patients

          -  Previous randomization in this study

          -  Enrollment in a related interventional study

          -  Child's class C liver disease Metastatic cancer with life expectancy &lt; 6 months
             Seizure disorder requiring anticonvulsant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Gunasekera, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Houston - Victoria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff C Cokenour, B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innovative Humanitarian Solutions</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minh Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innovative Humanitarian Solutions</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeff C Cokenour, B.S.</last_name>
    <phone>832-863-5690</phone>
    <email>jeff.cokenour@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Don Heath, B.S.</last_name>
    <email>donh@tamh.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lhasa Prefecture and surrounding villages</name>
      <address>
        <city>Lhasa</city>
        <state>Tibet</state>
        <zip>850000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Don Heath</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.innovativehs.net</url>
    <description>Innovative Humanitarian Solutions website</description>
  </link>
  <reference>
    <citation>Moreno-Reyes R, Egrise D, Boelaert M, Goldman S, Meuris S. Iodine deficiency mitigates growth retardation and osteopenia in selenium-deficient rats. J Nutr. 2006 Mar;136(3):595-600.</citation>
    <PMID>16484530</PMID>
  </reference>
  <reference>
    <citation>Köhrle J, Jakob F, Contempré B, Dumont JE. Selenium, the thyroid, and the endocrine system. Endocr Rev. 2005 Dec;26(7):944-84. Epub 2005 Sep 20. Review.</citation>
    <PMID>16174820</PMID>
  </reference>
  <reference>
    <citation>Xia Y, Hill KE, Byrne DW, Xu J, Burk RF. Effectiveness of selenium supplements in a low-selenium area of China. Am J Clin Nutr. 2005 Apr;81(4):829-34.</citation>
    <PMID>15817859</PMID>
  </reference>
  <reference>
    <citation>Esworthy RS, Yang L, Frankel PH, Chu FF. Epithelium-specific glutathione peroxidase, Gpx2, is involved in the prevention of intestinal inflammation in selenium-deficient mice. J Nutr. 2005 Apr;135(4):740-5.</citation>
    <PMID>15795427</PMID>
  </reference>
  <reference>
    <citation>Beckett GJ, Arthur JR. Selenium and endocrine systems. J Endocrinol. 2005 Mar;184(3):455-65. Review.</citation>
    <PMID>15749805</PMID>
  </reference>
  <reference>
    <citation>Moreno-Reyes R, Mathieu F, Boelaert M, Begaux F, Suetens C, Rivera MT, Nève J, Perlmutter N, Vanderpas J. Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy. Am J Clin Nutr. 2003 Jul;78(1):137-44.</citation>
    <PMID>12816783</PMID>
  </reference>
  <reference>
    <citation>Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, Dyer AR, Liu K, Greenland P. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999 Dec 1;282(21):2012-8.</citation>
    <PMID>10591383</PMID>
  </reference>
  <reference>
    <citation>Harris NS, Crawford PB, Yangzom Y, Pinzo L, Gyaltsen P, Hudes M. Nutritional and health status of Tibetan children living at high altitudes. N Engl J Med. 2001 Feb 1;344(5):341-7.</citation>
    <PMID>11172165</PMID>
  </reference>
  <reference>
    <citation>Utiger RD. Kashin-Beck disease--expanding the spectrum of iodine-deficiency disorders. N Engl J Med. 1998 Oct 15;339(16):1156-8.</citation>
    <PMID>9770565</PMID>
  </reference>
  <reference>
    <citation>Chanoine JP. Selenium and thyroid function in infants, children and adolescents. Biofactors. 2003;19(3-4):137-43. Review.</citation>
    <PMID>14757964</PMID>
  </reference>
  <reference>
    <citation>Molecular Biology of selenium with its implications for metabolism. Raymond F. Burke, Division of Gastroenterology, division of Medicine and center in molecular toxicology, Vanderbilt University school of medicine, Nashville, Tenn 37232, USA</citation>
  </reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <last_update_submitted>February 12, 2008</last_update_submitted>
  <last_update_submitted_qc>February 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Richard S. Gunasekera, Ph.D., Study Chair and P.I.</name_title>
    <organization>University of Houston - Victoria</organization>
  </responsible_party>
  <keyword>Kashin-Beck Disease</keyword>
  <keyword>Kashin-Beck Osteoarthropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kashin-Beck Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

